Vericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares of Stock

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $51.92, for a total value of $778,800.00. Following the completion of the transaction, the insider owned 1,990 shares of the company’s stock, valued at $103,320.80. This represents a 88.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Vericel Trading Up 5.5%

VCEL opened at $54.62 on Friday. The company’s fifty day moving average price is $41.01 and its two-hundred day moving average price is $38.90. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08. Vericel Corporation has a 1-year low of $28.95 and a 1-year high of $55.60.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The business had revenue of $85.37 million during the quarter, compared to analyst estimates of $77.95 million. The company’s revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the business posted $0.10 EPS. As a group, equities analysts forecast that Vericel Corporation will post 0.54 earnings per share for the current fiscal year.

Key Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently added to or reduced their stakes in the stock. MCF Advisors LLC lifted its stake in Vericel by 293.0% in the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 583 shares in the last quarter. Ameritas Advisory Services LLC purchased a new position in Vericel in the second quarter valued at about $36,000. Allworth Financial LP bought a new stake in Vericel in the second quarter valued at $60,000. Meeder Asset Management Inc. bought a new stake in shares of Vericel in the 1st quarter worth approximately $61,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of Vericel during the 2nd quarter valued at about $72,000.

Analyst Ratings Changes

VCEL has been the subject of a number of recent research reports. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday. TD Cowen lifted their price objective on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a report on Friday, July 31st. Truist Financial set a $65.00 price target on shares of Vericel in a research report on Friday. Finally, Canaccord Genuity Group set a $60.00 price objective on Vericel in a report on Thursday, July 30th. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and an average target price of $60.80.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.